PHIOW - Phio Pharmaceuticals Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1550
+0.0447 (+40.53%)
At close: 3:31PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1103
Open0.1972
Bid0.1700 x 1100
Ask0.0000 x 40700
Day's Range0.1251 - 0.1600
52 Week Range0.1251 - 0.1600
Volume25,993
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)2.21
PE Ratio (TTM)N/A
EPS (TTM)-11.2670
Earnings DateAug 10, 2020 - Aug 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020
      PR Newswire

      Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020

      Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced a poster presentation at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting which further details data demonstrating the potential of a TIGIT targeting INTASYL compound as an immuno-oncology therapeutic through the suppression of TIGIT in the tumor microenvironment (TME). The Phio poster presentation will also be available under the "Investors – Events and Presentations" section of the Company's website (click here).

    • Zacks Small Cap Research

      PHIO: Roussy’s Robert Details Developments in Melanoma Medicine

      By John Vandermosten, CFA NASDAQ:PHIO Phio Pharmaceuticals Unveils Clinical Plans for Neoadjuvant Intratumoral INTASYL in Melanoma Phio Pharmaceuticals Corp. (NASDAQ:PHIO) hosted a key opinion leader (KOL) call on Friday, June 12, 2020 featuring Caroline Robert, M.D., Ph.D., the Head of Dermatology Unit at Gustave Roussy and co-director of the Melanoma research Unit at INSERM 981 Paris-Sud

    • Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th
      PR Newswire

      Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th

      MARLBOROUGH, Mass., June 8, 2020 /PRNewsire/ – Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it will host a key opinion leader (KOL) call on intratumoral therapy with self-delivering RNAi at 8 a.m. ET on Friday, June 12, 2020.

    • Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity
      PR Newswire

      Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity

      Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive data from in vivo studies that show strong antitumoral efficacy with several of its INTASYL pipeline programs, including PH-762, PH-894 and PH-804. These results show that intratumoral delivery of INTASYL compounds inhibited tumor growth by overcoming the immunosuppressive tumor microenvironment (TME) as shown by changes in T cell composition and activation. Therefore, the Company believes these pipeline programs show great promise in the treatment of solid tumors. These data were presented during the ASCO 2020 Virtual Scientific Program (Abstract e15206: "Intratumoral use of self-delivering RNAi to reprogram the tumor microenvironment and boost the antitumor response").

    • PHIO: Intasyl Advantage vs. Gene Editing
      Zacks Small Cap Research

      PHIO: Intasyl Advantage vs. Gene Editing

      By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Milestones: ‣ Partnership/Sale of Dermatology and Ophthalmology Programs – TBD ‣ Expansion of collaboration with Helmholtz Zentrum München & Medigene – March 2020 ‣ IND enabling study results for PH-762 – 2020 ‣ PH-762 (ACT – Melanoma with partner) into clinic – 2H:20 ‣ PH-762 (IT – Melanoma) – 2021 ‣ PH-804 (ACT – with

    • Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020
      PR Newswire

      Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020

      Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced data analyzing the applicability of the INTASYL platform as a gene silencing technology that offers an alternative or complementary approach to gene editing technologies, such as CRISPR / Cas9, in the treatment of solid tumors. These data will be presented today at 5:30 p.m. ET at the 23rd Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) in virtual format. The Phio poster presentation will also be available under the "Investors – Events and Presentations" section of the Company's website (click here) approximately one hour after the event.

    • The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
      Benzinga

      The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

      Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV (NASDAQ: CNTG) * Forty Seven Inc (NASDAQ: FTSV)Down In The Dumps(Biotech Stocks Hitting 52-week lows on March 10) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * ADMA Biologics Inc (NASDAQ: ADMA) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Affimed NV (NASDAQ: AFMD) * Akari Therapeutics PLC (NASDAQ: AKTX) * Akcea Therapeutics Inc (NASDAQ: AKCA) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * Alkermes Plc (NASDAQ: ALKS) * Allena Pharmaceuticals Inc (NASDAQ: ALNA) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Anixa Biosciences Inc (NASDAQ: ANIX) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Aptevo Therapeutics Inc (NASDAQ: APVO) * Aptinyx Inc (NASDAQ: APTX) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Atossa Therapeutics Inc (NASDAQ: ATOS) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) * BioLife Solutions Inc (NASDAQ: BLFS) * bluebird bio Inc (NASDAQ: BLUE) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Celcuity Inc (NASDAQ: CELC) * Cerecor Inc (NASDAQ: CERC) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Enochian Biosciences Inc (NASDAQ: ENOB) * Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evolus Inc (NASDAQ: EOLS) * Exicure Inc (NASDAQ: XCUR) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Gossamer Bio Inc (NASDAQ: GOSS) * Gritstone Oncology Inc (NASDAQ: GRTS) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Heron Therapeutics Inc (NASDAQ: HRTX) * Incyte Corporation (NASDAQ: INCY) * INmune Bio Inc (NASDAQ: INMB) * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Jaguar Health Inc (NASDAQ: JAGX) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Kura Oncology Inc (NASDAQ: KURA) * Lantheus Holdings Inc (NASDAQ: LNTH) * TapImmune Inc. common stock (NASDAQ: MRKR) * MediciNova, Inc. (NASDAQ: MNOV) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Misonix Inc (NASDAQ: MSON) * Moleculin Biotech Inc (NASDAQ: MBRX) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO)ccccc * Neuronetics Inc (NASDAQ: STIM) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) * Plus Therapeutics Inc (NASDAQ: PSTV) * Polarityte Inc (NASDAQ: PTE) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * Precigen Inc (NASDAQ: PGEN) * Precipio Inc (NASDAQ: PRPO) * Radius Health Inc (NASDAQ: RDUS) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * Rubius Therapeutics Inc (NASDAQ: RUBY) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * SurModics, Inc. (NASDAQ: SRDX) * Synlogic Inc (NASDAQ: SYBX) * T2 Biosystems Inc (NASDAQ: TTOO) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Unum Therapeutics Inc (NASDAQ: UMRX) * Vericel Corp (NASDAQ: VCEL) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Mallinckrodt's Global Opioid Settlement Agreement Endorsed By New York State Mallinckrodt PLC (NYSE: MNK) said the New York State Attorney General Letitia James lent support to the company's previously announced global opioid settlement, joining 47 other states and U.S. Territory Attorneys General.The State of New York and Suffolk County, together with Mallinckrodt and SpecGx LLC, have jointly filed a motion to remove the companies from the New York State opioid trial.In pre-market trading, shares were rising 13.24% to $2.48.Kamada to Work On Treatment for Severely Ill COVID-19 Patients Israeli plasma-derived biopharma Kamada Ltd. (NASDAQ: KMDA) said it plans to initiate the development of an Anti-COVID-19 polyclonal immunoglobin using is its proprietary plasma derived IgG platform technology as a potential treatment for severely ill coronavirus patients."We are working with the Israeli regulatory authorities and local medical institutions to advance our program," said Amir London, CEO of Kamada.In pre-market trading, shares were up 6.23% to $5.80.FDA Approves Bristol-Myers' Opdivo-Yervoy Combo For Liver Cancer Bristol-Myers Squibb Co's (NYSE: BMY) said the FDA approved its sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma, previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar.Phio Pharma Announces Agreement to Develop Immune Enhancers Phio Pharmaceuticals Corp (NASDAQ: PHIO) has reached a new agreement with Medigene relating to its previously announced research collaboration with Helmholtz Zentrum Munchen to develop novel candidates for the use of Intasyl compounds in adoptive cell therapy to enhance immune function.The new agreement provides for Medigene contributing expertise regarding clinical development and proprietary research material. The company also has an option to an exclusive license for potential immune cell enhancers against certain fee payments.Phio shares rallied 15.30% to $3.24 in after-hours trading.NuCana's Ovarian Cancer Drug Shows Favorable Disease Control In Midstage Study NuCana PLC (NASDAQ: NCNA) announced preliminary results from part one of the Phase 2 study of single-agent Acelarin in difficult-to-treat patients with platinum-resistant ovarian cancer, which showed that out of the 45 evaluable patients, one patient achieved a complete response and two patients achieved partial responses, while 16 achieved stable disease."We are pleased with this favorable disease control rate and Acelarin's ability to achieve confirmed complete and partial responses in this very heavily pre-treated patient population," said Hugh Griffith, CEO of NuCana.Separately, the company reported fourth-quarter results showing a wider loss.View more earnings on MNKNuCana shares rose 7.25% to $7.25 in after-hours trading.Sophiris Bio Shares to Be Delisted From Nasdaq, Effective March 12 Sophiris Bio Inc (NASDAQ: SPHS), which is evaluating its topsalysin in late-stage clinical trials for urological diseases, said the Nasdaq Officer of General Counsel informed the company that the Nasdaq Hearing Panel has determined to delist its shares from the Nasdaq. Trading in the company's shares are to be suspended, effective at the open of business March 12.The company said it expects its shares to be eligible for trading on the OTC.The delisting comes in the wake of the company flouting listing standards pertaining to the minimum $2.5 million stockholder's equity requirement.The stock plummeted 39.58% to 35 cents in the after-hours trading.J&J's Lung Cancer Therapy Gets Breakthrough Designation Johnson & Johnson (NYSE: JNJ) said its Janssen unit's JNJ-61186372 has been granted Breakthrough Therapy Designation by the FDA for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.Roche's Biomarker-based Screening Test For Cervical Cancer Approved by FDARoche Holdings AG Basel ADR (OTC: RHHBY) said the FDA approved its CINtec PLUS Cytology, as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for HPV using the cobas 4800 HPV Test.Altimmune Soars Despite No NewsAltimmune Inc (NASDAQ: ALT) shares were sharply higher in after-hours trading, although there was no release from the company.Earnings RA Medical Systems Inc (NYSE: RMED) reported a decline in is fourth-quarter revenues from $2 million in 2018 to $1.4 million in 2019. The net loss per share narrowed from $1.18 to 72 cents. Analysts estimated a loss of $1.15 per share.The stock plunged 39.72% to 85 cents in after-hours trading.Fulgent Genetics Inc's (NASDAQ: FLGT) fourth-quarter revenues climbed 48% year-over-year to $8.4 million and the company reported non-GAAP EPS of 4 cents, in line with the consensus estimate.The stock 4.92% to $14.50 in after-hours trading.Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) reported fourth-quarter revenues of $2.07 million in 2019 compared to no revenues a year ago. The net loss per share narrowed from 16 cents to 5 cents, while analysts estimated a loss of 7 cents per share.The stock slipped 5.21% to 91 cents in after-hours trading.Offerings Kala Pharmaceuticals Inc (NASDAQ: KALA) said it has priced its underwritten public offering of 16 million shares at $7.89 per share, for generating gross proceeds of $126.2 million. The company expects the offering to close March 13.In premarket trading Wednesday, Kala shares were adding 11.53% to $8.80.On The Radar Earnings • Xeris Pharma (before the market open) • Liquidia Technologies Inc (NASDAQ: LQDA) (before the market open) • Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) • INmune Bio Inc (NASDAQ: INMB) (before the market open) • Clearside Biomedical Inc (NASDAQ: CLSD) (after the close) • Calithera Biosciences Inc (NASDAQ: CALA) (after the close) • Unity Biotechnology Inc (NASDAQ: UBX) (after the close) • Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) • Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) • BioLife Solutions Inc (NASDAQ: BLFS) (after the close) • Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close) • Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) • Pfenex Inc (NYSE: PFNX) (after the close) • Arcturus Therapeutics Ltd (NASDAQ: ARCT) (after the close) • Novavax, Inc. (NASDAQ: NVAX) (after the close) • Global Cord Blood Corp (NYSE: CO) (after the close)See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Benzinga

      The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

      Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...

    • Benzinga

      The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

      Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

    • PHIO: Third Quarter 2019 Financial & Operational Update
      Zacks Small Cap Research

      PHIO: Third Quarter 2019 Financial & Operational Update

      By John Vandermosten, CFA NASDAQ:PHIO Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported third quarter 2019 results and filed its Form 10-Q on November 12, 2019. Since the beginning of the year, the company has announced a several new collaborations with partners including Glycostem Therapeutics, Helmholtz Zentrum Munchen and Carisma Therapeutics. Research and development efforts have put the

    • Zacks Small Cap Research

      PHIO: Overcoming Immune Checkpoints

      By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported second quarter 2019 results and filed its Form 10-Q on August 12, 2019. Since ...